Retatrutide + Cagrilintide (Reta + Cagri)
Also known as: Reta + Cagri Stack, Triple Agonist + Amylin Stack (4-Receptor Protocol), Tirz / Reta + Cagri Plateau Stack
Studied in published research — not a medical recommendation. Primary protocol (Staggered Separate-Vial 8:1 Protocol): 2.0–4.0 mg Retatrutide (Monday) + 0.25–0.50 mg Cagrilintide (Thursday), Weekly (staggered 3.5 days apart).
Weekly (staggered 3.5 days apart)
Research-reported range (no primary dosing study). Keep Retatrutide and Cagrilintide in separate vials so Cagrilintide stays at 0.25–0.5 mg while Retatrutide titrates from 2 mg -> 4 mg -> 6 mg
Subcutaneous injection (separate syringes)
Published peer-reviewed research & clinical protocols
No verified human half-life on file for this compound
A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.
All U-100: 100 units = 1 mL. 5 doses in the vial at the low end (2 doses at the high end).
Save Retatrutide + Cagrilintide (Reta + Cagri) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.
Retatrutide + Cagrilintide (Reta + Cagri) supplier & $/mg comparison.
At a Glance · 2026 FDA / 503A / WADA / Evidence Profile
What is a GLP-1 Agonist?
A molecule that mimics glucagon-like peptide-1 (GLP-1), a hormone that regulates blood sugar, slows gastric emptying, and reduces appetite. Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are GLP-1 agonists. These are peptides, but they are marketed and prescribed as pharmaceutical drugs.
Bottom Line Up Front
Because Retatrutide's glucagon receptor activity boosts basal metabolic rate with gentler early appetite suppression than Tirzepatide, researchers frequently layer low-dose Cagrilintide (0.25–0.5 mg/week) in an 8:1 to 10:1 separate-vial ratio (e.g., 2–4 mg Retatrutide + 0.25–0.5 mg Cagrilintide staggered 3.5 days apart).
Published preclinical & translational clinical protocols
Large multi-year outcomes in healthy non-clinical cohorts
None
3 (0 human)
EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. Retatrutide + Cagrilintide (Reta + Cagri) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.
Overview
The Retatrutide + Cagrilintide ('Reta + Cagri') stack combines Eli Lilly's triple incretin/glucagon agonist (GLP-1R / GIPR / GCGR) with Novo Nordisk's long-acting amylin analog (Cagrilintide) for a 4-receptor metabolic protocol. While Retatrutide drives unmatched hepatic fat oxidation and resting energy expenditure via glucagon agonism, some users transitioning from high-dose Tirzepatide notice more 'food noise' at early Retatrutide doses (2–4 mg). Layering 0.25–0.5 mg of Cagrilintide mid-week restores potent amylin-mediated satiety without needing to push Retatrutide to high doses prematurely.
Mechanisms of Action
- Retatrutide activates GLP-1, GIP, and Glucagon receptors to increase hepatic lipid oxidation and resting energy expenditure
- Cagrilintide activates hindbrain amylin (AMY1–3) and calcitonin receptors to provide rapid meal termination and curb food noise
- 4-receptor coverage (GLP-1R + GIPR + GCGR + AMYR) targets both caloric intake and thermogenic output
Common Ratios, Vial Formats & Dosing Breakdown
Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.
8:1 to 10:1 Separate-Vial Staggered Stack (Recommended)
10mg Retatrutide vial + 5mg Cagrilintide vial (separate)
2.0–4.0 mg Retatrutide (Day 1) + 0.25–0.50 mg Cagrilintide (Day 4)
Why this ratio: Staggering injections by 3.5 days smooths appetite control across the entire week and allows independent titration of each compound.
1:1 Pre-Mixed Blend Vial (Ratio Warning)
5mg Retatrutide / 5mg Cagrilintide (10mg total)
Only suitable at 0.25–0.5 mg starting doses
Why this ratio: Warning: A 1:1 pre-mixed Reta/Cagri vial locks both compounds together. Drawing 4 mg of Retatrutide from a 1:1 vial would deliver 4 mg of Cagrilintide (8x–16x the typical 0.25–0.5 mg Cagri dose), causing severe GI stasis and lethargy.
Research Protocols
Summaries of published research. For educational purposes only.
| Protocol Name | Source | Dose | Frequency | Duration | Route | Evidence | Link | Save |
|---|---|---|---|---|---|---|---|---|
| Staggered Separate-Vial 8:1 Protocol | reported protocol | 2.0–4.0 mg Retatrutide (Monday) + 0.25–0.50 mg Cagrilintide (Thursday) | Weekly (staggered 3.5 days apart) | 12–24 weeks | Subcutaneous injection (separate syringes) | human | — |
Metabolic, Hepatic & Incretin Safety Biomarker Panel (Retatrutide + Cagrilintide (Reta + Cagri))
Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.
HbA1c & Fasting Insulin (HOMA-IR)
Day 0 + Wk 6–8Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.
Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.
ALT, AST & GGT Liver Enzymes
Day 0 + Wk 6–8Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.
Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.
ApoB, Triglycerides & Advanced Lipid Panel
Day 0 + Wk 6–8Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.
Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.
Serum Lipase, Amylase & eGFR / Cystatin C
Day 0 + Wk 6–8Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.
Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.
Community Outcomes
Community Data Coming Soon
Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!
Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.
Important Warnings
- •Do NOT use a 1:1 pre-mixed vial once Retatrutide dose exceeds 0.5–1.0 mg/week; always use separate vials
- •Ensure high protein intake (1.6g+/kg) and electrolyte hydration due to combined satiety + glucagon diuresis
Where to get Retatrutide + Cagrilintide (Reta + Cagri), baseline labs & clinician oversight.
Ascension Peptides (US Vials)
MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.
SwissChems & Limitless Biotech
Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).
Superpower Labs & 503A Telehealth
Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.
Where to buy Retatrutide + Cagrilintide (Reta + Cagri): best verified price
Prices checked Nov 11, 2026 · sorted by $/mg · RUO
- 1. Elite Research USA — $5.33/mg (15mg vial, $80.00)
Where is the cheapest place to buy Retatrutide + Cagrilintide (Reta + Cagri)?
As of Nov 11, 2026, the lowest verified US domestic single-vial price we found is Elite Research USA at $5.33/mg (15mg vial, $80.00). We compared 1 US supplier with live, checked prices.
How much does Retatrutide + Cagrilintide (Reta + Cagri) cost per mg?
Verified US domestic prices currently range from $5.33/mg to $5.33/mg depending on supplier and vial size. Larger vials usually lower the $/mg.
How are these prices verified?
Each price is read from the supplier's own product page or store data and divided by the vial's mg. Suppliers we could not verify are left out rather than estimated. Tables sort strictly by $/mg, never by partner status. Prices are re-checked weekly on our price index.
Is Retatrutide + Cagrilintide (Reta + Cagri) approved for human use?
Products from these suppliers are sold for laboratory research use only (RUO). This page is an educational price reference, not medical advice.
All compounds $/mgWeekly $/mg price indexReconstitution calculatorFree cheat sheet
Peptide Reconstitution & U-100 Syringe Cheat Sheet
Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.
Vendor vs vendor: price per mg
Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.
- Ascension vs SwissChems (3 shared compounds)
- Elite vs SwissChems (3 shared compounds)
- Elite vs Ascension (26 shared compounds)
- Protide vs SwissChems (3 shared compounds)
- Protide vs Ascension (6 shared compounds)
- Ameano vs SwissChems (3 shared compounds)
- Ameano vs Ascension (4 shared compounds)
- Swift vs Ascension (23 shared compounds)
- BioLongevity vs Ascension (16 shared compounds)
- Peptyes vs SwissChems (3 shared compounds)
- Peptyes vs Elite (20 shared compounds)
- Peptyes vs Swift (17 shared compounds)
- Peptyes vs Pure (17 shared compounds)
- Peptyes vs Ascension (20 shared compounds)
Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →
Common questions
How many peptides are in the database?
100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.
Where can I compare peptide prices?
Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.